来源:药渡撰文:幻目 编辑:维他命2025年上半年,全球制药行业格局迎来新变化!随着各大跨国药企陆续发布中期财报,GLP-1减肥药、肿瘤免疫疗法和专利悬崖成为关键词。礼来、诺和诺德凭借爆款减肥药强势增长,而默沙东和百时美施贵宝由于成熟产品增势放缓、医保政策、专利悬崖等原因销售额下降。结合最新财报数据,本文盘点了2025上半年排名前10家全球药企营收业绩情况。表1. 制药巨头2025 H1...
Source Link来源:药渡撰文:幻目 编辑:维他命2025年上半年,全球制药行业格局迎来新变化!随着各大跨国药企陆续发布中期财报,GLP-1减肥药、肿瘤免疫疗法和专利悬崖成为关键词。礼来、诺和诺德凭借爆款减肥药强势增长,而默沙东和百时美施贵宝由于成熟产品增势放缓、医保政策、专利悬崖等原因销售额下降。结合最新财报数据,本文盘点了2025上半年排名前10家全球药企营收业绩情况。表1. 制药巨头2025 H1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.